Trelegy gets FDA thumbs-up for asthma, becoming first triple-combo therapy in the US
One of GSK’s biggest blockbusters just got a whole new indication to play with.
Trelegy Ellipta received the green light from the FDA late Wednesday for adults with asthma, becoming the first triple-therapy combination drug to treat the condition in the United States. The medicine had been approved for use in chronic obstructive pulmonary disease since 2017 and functions as a once-daily inhalation.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.